Statistical analysis of 32 patients with nasopharyngeal Carcinoma

Ryoichi Fujii, Yorihisa Imanishi, Toshiki Tomita, Koji Sakamoto, Seiji Shigetomi, Noboru Habu, Kuninori Ootsuka, Yoichiro Sato, Hiroyuki Ozawa, Taku Yamashita, Masato Fujii, Naoyuki Shigematsu, Kaoru Ogawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In order to assess the clinical outcome and prognostic factors of patients with nasopharyngeal carcinoma (NPC) who were initially treated in the Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine between 1997 and 2006, statistical analyses were performed based on the patient medical records. Cause-specific survival (CSS) and disease-free survival (DFS) in all cases (stage I to IV, n = 32) and advanced cases (stage III and IV, n = 22) were estimated using the Kaplan-Meier method. The independent prognostic values of the clinical and therapeutic factors were determined using multivariate Cox proportional hazards models. Results: The 5-year CSS/DFS were 43.4%/34.8% in all cases and 34.596/29.8% in advanced cases. Multivariate analysis revealed that, in all cases, the independent prognostic factors for CSS were age ≥ 61 vs. ≤60, risk ratio (RR) =5.717, p = 0.006), T-stage (3/4 vs. 1/2, RR = 6.957, p = 0.004), and the use of platinum agents (unused vs. used, RR = 3.911, p = 0.012), whereas those for DFS were T-stage (3/4 vs. 1/2, RR=3.499, p = 0.019) and the use of platinum agents (unused vs. used, RR=2.947, p = 0.028). In advanced cases, the use of platinum agents alone was significant for both CSS (RR = 4.503, p = 0.023)and DFS (RR=4.218, p = 0.014). The patients who received neoadjuvant chemotherapy (NAC) showed better CSS and DFS than the patients who did not (p = 0.066 and p = 0.025, respectively) in a univariate analysis (Log-rank test), although no significant difference was seen between these groups in the multivariate analysis. Conclusion: The advantage of the administration of platinum agents in the treatment of NPC was statistically corroborated even in our study with its small sample size. As agents combined with chemoradiotherapy, the efficacy of do-cetaxel alone did not seem comparable to that of platinum agents. The docetaxel-CDDP-5-FU regimen applied as NAC was suggested to be possibly beneficial for advanced cases of NPC.

Original languageEnglish
Pages (from-to)773-782
Number of pages10
JournalJournal of Otolaryngology of Japan
Volume115
Issue number8
DOIs
Publication statusPublished - 2012 Aug

Fingerprint

Odds Ratio
Platinum
Disease-Free Survival
Survival
docetaxel
Multivariate Analysis
Drug Therapy
Otolaryngology
Chemoradiotherapy
Nasopharyngeal carcinoma
Proportional Hazards Models
Fluorouracil
Sample Size
Medical Records
Neck
Head
Medicine
Therapeutics

Keywords

  • Chemoradiotherapy
  • Independent prognostic factor
  • Nasopharyngeal carcinoma
  • Platinum agents

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Fujii, R., Imanishi, Y., Tomita, T., Sakamoto, K., Shigetomi, S., Habu, N., ... Ogawa, K. (2012). Statistical analysis of 32 patients with nasopharyngeal Carcinoma. Journal of Otolaryngology of Japan, 115(8), 773-782. https://doi.org/10.3950/jibiinkoka.115.773

Statistical analysis of 32 patients with nasopharyngeal Carcinoma. / Fujii, Ryoichi; Imanishi, Yorihisa; Tomita, Toshiki; Sakamoto, Koji; Shigetomi, Seiji; Habu, Noboru; Ootsuka, Kuninori; Sato, Yoichiro; Ozawa, Hiroyuki; Yamashita, Taku; Fujii, Masato; Shigematsu, Naoyuki; Ogawa, Kaoru.

In: Journal of Otolaryngology of Japan, Vol. 115, No. 8, 08.2012, p. 773-782.

Research output: Contribution to journalArticle

Fujii, R, Imanishi, Y, Tomita, T, Sakamoto, K, Shigetomi, S, Habu, N, Ootsuka, K, Sato, Y, Ozawa, H, Yamashita, T, Fujii, M, Shigematsu, N & Ogawa, K 2012, 'Statistical analysis of 32 patients with nasopharyngeal Carcinoma', Journal of Otolaryngology of Japan, vol. 115, no. 8, pp. 773-782. https://doi.org/10.3950/jibiinkoka.115.773
Fujii R, Imanishi Y, Tomita T, Sakamoto K, Shigetomi S, Habu N et al. Statistical analysis of 32 patients with nasopharyngeal Carcinoma. Journal of Otolaryngology of Japan. 2012 Aug;115(8):773-782. https://doi.org/10.3950/jibiinkoka.115.773
Fujii, Ryoichi ; Imanishi, Yorihisa ; Tomita, Toshiki ; Sakamoto, Koji ; Shigetomi, Seiji ; Habu, Noboru ; Ootsuka, Kuninori ; Sato, Yoichiro ; Ozawa, Hiroyuki ; Yamashita, Taku ; Fujii, Masato ; Shigematsu, Naoyuki ; Ogawa, Kaoru. / Statistical analysis of 32 patients with nasopharyngeal Carcinoma. In: Journal of Otolaryngology of Japan. 2012 ; Vol. 115, No. 8. pp. 773-782.
@article{dd10a3b861eb4ca1bb593bd8d15a55f4,
title = "Statistical analysis of 32 patients with nasopharyngeal Carcinoma",
abstract = "In order to assess the clinical outcome and prognostic factors of patients with nasopharyngeal carcinoma (NPC) who were initially treated in the Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine between 1997 and 2006, statistical analyses were performed based on the patient medical records. Cause-specific survival (CSS) and disease-free survival (DFS) in all cases (stage I to IV, n = 32) and advanced cases (stage III and IV, n = 22) were estimated using the Kaplan-Meier method. The independent prognostic values of the clinical and therapeutic factors were determined using multivariate Cox proportional hazards models. Results: The 5-year CSS/DFS were 43.4{\%}/34.8{\%} in all cases and 34.596/29.8{\%} in advanced cases. Multivariate analysis revealed that, in all cases, the independent prognostic factors for CSS were age ≥ 61 vs. ≤60, risk ratio (RR) =5.717, p = 0.006), T-stage (3/4 vs. 1/2, RR = 6.957, p = 0.004), and the use of platinum agents (unused vs. used, RR = 3.911, p = 0.012), whereas those for DFS were T-stage (3/4 vs. 1/2, RR=3.499, p = 0.019) and the use of platinum agents (unused vs. used, RR=2.947, p = 0.028). In advanced cases, the use of platinum agents alone was significant for both CSS (RR = 4.503, p = 0.023)and DFS (RR=4.218, p = 0.014). The patients who received neoadjuvant chemotherapy (NAC) showed better CSS and DFS than the patients who did not (p = 0.066 and p = 0.025, respectively) in a univariate analysis (Log-rank test), although no significant difference was seen between these groups in the multivariate analysis. Conclusion: The advantage of the administration of platinum agents in the treatment of NPC was statistically corroborated even in our study with its small sample size. As agents combined with chemoradiotherapy, the efficacy of do-cetaxel alone did not seem comparable to that of platinum agents. The docetaxel-CDDP-5-FU regimen applied as NAC was suggested to be possibly beneficial for advanced cases of NPC.",
keywords = "Chemoradiotherapy, Independent prognostic factor, Nasopharyngeal carcinoma, Platinum agents",
author = "Ryoichi Fujii and Yorihisa Imanishi and Toshiki Tomita and Koji Sakamoto and Seiji Shigetomi and Noboru Habu and Kuninori Ootsuka and Yoichiro Sato and Hiroyuki Ozawa and Taku Yamashita and Masato Fujii and Naoyuki Shigematsu and Kaoru Ogawa",
year = "2012",
month = "8",
doi = "10.3950/jibiinkoka.115.773",
language = "English",
volume = "115",
pages = "773--782",
journal = "Journal of Otolaryngology of Japan",
issn = "0030-6622",
publisher = "Oto-Rhino-Laryngological Society of Japan Inc.",
number = "8",

}

TY - JOUR

T1 - Statistical analysis of 32 patients with nasopharyngeal Carcinoma

AU - Fujii, Ryoichi

AU - Imanishi, Yorihisa

AU - Tomita, Toshiki

AU - Sakamoto, Koji

AU - Shigetomi, Seiji

AU - Habu, Noboru

AU - Ootsuka, Kuninori

AU - Sato, Yoichiro

AU - Ozawa, Hiroyuki

AU - Yamashita, Taku

AU - Fujii, Masato

AU - Shigematsu, Naoyuki

AU - Ogawa, Kaoru

PY - 2012/8

Y1 - 2012/8

N2 - In order to assess the clinical outcome and prognostic factors of patients with nasopharyngeal carcinoma (NPC) who were initially treated in the Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine between 1997 and 2006, statistical analyses were performed based on the patient medical records. Cause-specific survival (CSS) and disease-free survival (DFS) in all cases (stage I to IV, n = 32) and advanced cases (stage III and IV, n = 22) were estimated using the Kaplan-Meier method. The independent prognostic values of the clinical and therapeutic factors were determined using multivariate Cox proportional hazards models. Results: The 5-year CSS/DFS were 43.4%/34.8% in all cases and 34.596/29.8% in advanced cases. Multivariate analysis revealed that, in all cases, the independent prognostic factors for CSS were age ≥ 61 vs. ≤60, risk ratio (RR) =5.717, p = 0.006), T-stage (3/4 vs. 1/2, RR = 6.957, p = 0.004), and the use of platinum agents (unused vs. used, RR = 3.911, p = 0.012), whereas those for DFS were T-stage (3/4 vs. 1/2, RR=3.499, p = 0.019) and the use of platinum agents (unused vs. used, RR=2.947, p = 0.028). In advanced cases, the use of platinum agents alone was significant for both CSS (RR = 4.503, p = 0.023)and DFS (RR=4.218, p = 0.014). The patients who received neoadjuvant chemotherapy (NAC) showed better CSS and DFS than the patients who did not (p = 0.066 and p = 0.025, respectively) in a univariate analysis (Log-rank test), although no significant difference was seen between these groups in the multivariate analysis. Conclusion: The advantage of the administration of platinum agents in the treatment of NPC was statistically corroborated even in our study with its small sample size. As agents combined with chemoradiotherapy, the efficacy of do-cetaxel alone did not seem comparable to that of platinum agents. The docetaxel-CDDP-5-FU regimen applied as NAC was suggested to be possibly beneficial for advanced cases of NPC.

AB - In order to assess the clinical outcome and prognostic factors of patients with nasopharyngeal carcinoma (NPC) who were initially treated in the Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine between 1997 and 2006, statistical analyses were performed based on the patient medical records. Cause-specific survival (CSS) and disease-free survival (DFS) in all cases (stage I to IV, n = 32) and advanced cases (stage III and IV, n = 22) were estimated using the Kaplan-Meier method. The independent prognostic values of the clinical and therapeutic factors were determined using multivariate Cox proportional hazards models. Results: The 5-year CSS/DFS were 43.4%/34.8% in all cases and 34.596/29.8% in advanced cases. Multivariate analysis revealed that, in all cases, the independent prognostic factors for CSS were age ≥ 61 vs. ≤60, risk ratio (RR) =5.717, p = 0.006), T-stage (3/4 vs. 1/2, RR = 6.957, p = 0.004), and the use of platinum agents (unused vs. used, RR = 3.911, p = 0.012), whereas those for DFS were T-stage (3/4 vs. 1/2, RR=3.499, p = 0.019) and the use of platinum agents (unused vs. used, RR=2.947, p = 0.028). In advanced cases, the use of platinum agents alone was significant for both CSS (RR = 4.503, p = 0.023)and DFS (RR=4.218, p = 0.014). The patients who received neoadjuvant chemotherapy (NAC) showed better CSS and DFS than the patients who did not (p = 0.066 and p = 0.025, respectively) in a univariate analysis (Log-rank test), although no significant difference was seen between these groups in the multivariate analysis. Conclusion: The advantage of the administration of platinum agents in the treatment of NPC was statistically corroborated even in our study with its small sample size. As agents combined with chemoradiotherapy, the efficacy of do-cetaxel alone did not seem comparable to that of platinum agents. The docetaxel-CDDP-5-FU regimen applied as NAC was suggested to be possibly beneficial for advanced cases of NPC.

KW - Chemoradiotherapy

KW - Independent prognostic factor

KW - Nasopharyngeal carcinoma

KW - Platinum agents

UR - http://www.scopus.com/inward/record.url?scp=84866096650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866096650&partnerID=8YFLogxK

U2 - 10.3950/jibiinkoka.115.773

DO - 10.3950/jibiinkoka.115.773

M3 - Article

C2 - 23016269

AN - SCOPUS:84866096650

VL - 115

SP - 773

EP - 782

JO - Journal of Otolaryngology of Japan

JF - Journal of Otolaryngology of Japan

SN - 0030-6622

IS - 8

ER -